https://www.arbelebio.com https://www.arbelebio.com/about https://www.arbelebio.com/careers https://www.arbelebio.com/cadherin-17 https://www.arbelebio.com/research https://www.arbelebio.com/pipeline https://www.arbelebio.com/news https://www.arbelebio.com/contact https://www.arbelebio.com/terms-and-conditions https://www.arbelebio.com/privacy https://www.arbelebio.com/cookie-policy https://www.arbelebio.com/post/a-cold-target-sparking-a-hot-revolution https://www.arbelebio.com/post/arb202-continues-dosing https://www.arbelebio.com/post/arb202-early-safety-data-asco-breakthrough-2023 https://www.arbelebio.com/post/arbele-7th-anniversary-opening-tibtech-cancer-diagnostics https://www.arbelebio.com/post/arbele-announces-phase-1-first-in-human-study-of-cdh17xcd3-bispecific-t-cell-engager-for-treatment-of-gastrointestinal-cancers https://www.arbelebio.com/post/arbele-announces-strategic-collaborations-on-ai-precision-oncology-and-manufacturing-to-advance-cdh17-targeted-immunotherapeutics https://www.arbelebio.com/post/arbele-bio-named-emerging-biotech-company-of-the-great-bay-area https://www.arbelebio.com/post/arbele-joint-venture-cma-cell-banking https://www.arbelebio.com/post/arbele-presented-5-posters-in-aacr2024 https://www.arbelebio.com/post/arbele-presenting-at-esmo-2024 https://www.arbelebio.com/post/arbele-receives-fda-orphan-drug-designation-for-arb1002-an-anti-cdh17-antibody-drug-conjugate-for-the-treatment-of-pancreatic-cancer https://www.arbelebio.com/post/arbele-wins-asian-fund-for-cancer-research-inaugural-2020-brace-award-venture-competition https://www.arbelebio.com/post/arbele-wins-top-prize-at-bcics-4th-annual-biomedical-pitch-competition https://www.arbelebio.com/post/chime-biologics-and-arbele-announce-strategic-collaboration-at-biohk-2025-signing-ceremony https://www.arbelebio.com/post/the-diagnostic-significance-of-cdh17-positive-circulating-tumor-cells-in-patients-with-colorectal-cancer